The FDA approved brentuximab vedotin (Adcetris) in combination with lenalidomide (Revlimid) and rituximab for relapsed or ...

Following a disappointing Q3 FY25 report showing a 37.75% profit drop, NATCO Pharma shares plummeted 19%, reflecting ongoing ...

Shares of NATCO Pharma plunged 19 per cent on Thursday, February 13, following the company’s disappointing Q3 FY25 results, ...

Stock analysts noted Natco Pharma’s missed consensus Q3 estimates on both revenue and Ebitda margin fronts due to lack of ...

Natco Pharma plans to launch its CTPR products very shortly, which is estimated to have a market size of over ₹2,000 crore in India. Natco Pharma shares surged after the drug maker unveiled the first ...

Shares of NATCO Pharma plunged 20% on Thursday, February 13, after the company reported a decline in revenue, profit in Q3; ...